Investor Presentation

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 3rd August 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sirs, Subject: Presentation of Analyst / Institutional Investor Meetings Pursuant to Regulation 30 read with Part A of Schedule Ill of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the presentation to be made in Investors / Analysts Call and the same is also being uploaded on the website of the Company. Thanking you, Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary CIN: L24239MH1924PLC001151 GlaxoSmithKline Pharmaceuticals Limited gsk.com Bhushan Akshikar, Managing Director Mr. Bhushan Akshikar has been the MD of GSK India since Q3 2022. He brings over 15 years of leadership experience within GSK in key roles across India, Middle East, Russia CIS & Africa region. Prior to joining GSK, Bhushan spent 15 years with Johnson & Johnson, in local and regional positions in India, S. Korea and Belgium. Ronojit Biswas, Chief Financial Officer Mr. Ronojit Biswas has been the CFO of GSK India since April 2026. He brings over 25 years of experience across global finance roles, spanning India, Vietnam, Singapore, Brazil and the UK. Prior to this role, Ronojit served as Senior Finance Director – Global Product Strategy for the General Medicines Therapy Area and has previously been Regional Controller (International) and CFO for GSK’s Brazil and Vietnam businesses. GSK India’s Key Focus areas to drive growth aligned to global priorities Deliver Simplify how Accelerate growth we work Established portfolio – deliver Reduce complexity, focus resources on Focus on innovation & accelerate competitive performance; what matters most and embrace launch of pipeline products Innovative portfolio – deliver ambition AI/tech to drive agility IPM Q1 FY27 IPM grew at 13.5%, GSK grew faster than its Rep Market IPM sees growth largely on account GSK’s Rep market grew at 10% with both GSK’s performance in metro class and of price. Vx and Gen Med outperforming the market specialties outgrew the market GSK portfolio* has maintained its 8.7% leadership with 23% share in rep 1.9% market 3.0% 12% 13.6% Rep mar 10% 11.1% GSK portfolio 11% 33% 7.4% 8.2% GSK 31% Apr-May’26 Price: 2.4%, Vol: 4.4%, NI: 1.8% IPM Gr. 20% 16% GSK Gen Med portfolio* has maintained its leadership with 22% Metros T1 T2-6 Rural Chronic grew better vs acute share in rep market IPM 32% 32% 20% 16% increasing its industry contribution (+4.3%) (+1.6%) (+2%) (-0.6%) Rep mar 9% Acute 60% 11% GPs continue to dominate with 40% Rxns volume and growth faster than Specialty and GSK Ged Med 11% Super specialty Rxns portfolio Chronic 40% Price: 3.2%, Vol: 3.2%, NI: 3% 5.5% 4.9% 4.8% % Growth GSK Vx portfolio* has maintained MNCs ahead of Indian players with its leadership with 27% share in rep respect to growth market GSK Rep mar 20% Indian 84% 13% 40% 36% 24% GSK Vx 14% MNCs 16% 15% GP Specialty Super Spec portfolio % Growth Price: -2%, Vol: 13.3%, NI: 5.4% IPM 45% (4.3%); 43% (4.9%) ; 12% (-0.7%) Source: IQVIA Jun’26 dataset (MQT); *includes all Gen Med & Vaccine brands except GoA portfolio & the discontinued brands ecirP emuloV IN Within Acute, key therapies like Pain, derma grew at 11%; AI grew slower 13.3 CARDIAC 16.9 10.5 ANTI INF 8.5 10.5 GASTRO 10 17.3 9.0 ANTI DIABETIC 8.7 PAIN 13.2 7.6 RESPIRATORY 11.3 7.5 VIT/MIN/NUT 16.3 6.8 DERMA 11.3 6.0 NEURO / CNS 12.9 4.7 GYNAEC. 12.1 1.5 HORMONES 11.5 VACCINES 18.5 % Contri % Value Growth GSK’s key brands remained competitive in the market in Q1 FY27 GENERAL MEDICINES VACCINES SPECIALTY 1 Gen Meds1 market share improved (+0.6%val Established Vaccines continues to lead the Building equity in the MS gain, Val EI 101); key brands delivered overall Vx market with 26.1% Val MS2 Unit EI Respiratory Segment competitive performance 95 & Val EI 93 MS Q1 FY26 Q1 FY27 Val 26.7 26.6 3 Establishing adult immunization as a Unit 33.3 33.9 category through Shingrix; driving 2026 New Patient Update 3500+ Brand Val EI Val MS (G/L) Val Gr growth through the CVMD opportunity Severe asthma Monthly units (Q1 FY27) (Q1 FY27) (Q1 FY27) patients benefitted (maintaining >19% vs Augmentin 105 22% 12.80% (1.0%) 2.6k Rxers for (39% YOY avg. units post LoE sales Calpol 106 31.2% (1.6%) 8.10% post LOE in Apr 2025) growth) T-Bact 105 57.5% 17.90% (2.6%) Ceftum 101 32.7% 7.60% (0.2%) Key Promoted Brands 100 23.4% (0%) 11.30% 5 Strong foundation in Oncology *1% Unit Market Share Gain New Patient Uptake Improving our SoV and Elevating 360K+ 7.7Mn+ customer experience through digital innovation Unique HCPs reached4 Touchpoints4 Source: IQVIA Jun'26 dataset (MQT), Internal data; 1excludes GOA; 2 MAT Val MS; 3 Distributed brands includes the GoApptiv portfolio, 4Both F2F+ Digital Financial Highlights : Q1 FY 26-27 (Standalone) Delivering strong growth with continued portfolio transformation Revenue EBITDA PAT ₹924cr ₹293cr ₹253cr Growth +15% Margin: 31.7% (+50 bps) Margin: 27.6% (+200 bps) Growth +17% Growth +24% Revenue growth +15% EBITDA margin +50 bps (YoY) PAT +200 bps (YoY)  Sales growth driven by execution excellence;  EBITDA improved on the back of gross  PAT stepped up on consistent gross margin portfolio transformation strategy and favourable margin improvement improvement; one-off dividend from Biddle base effect compared to PY Sawyer Limited (100% subsidiary)  Gross margin improved +150 bps on pricing  Innovation* portfolio accounts for 7% (PY 4%) of and favorable mix offset by higher EGOL  EPS for Q1 @ 14.95 (+24%) total sales, driving 1/4th of headline growth. and other costs Building momentum with Oncology launches &  Sustained focus to strengthen and optimize New respiratory  SG&A as a % of sales higher by 1%, mainly the balance sheet driven by investments in core brands & new  General medicines growth led by brands product Augmentin, Ceftum and T-Bact  Pead Vaccines continued leadership in the self pay private pediatric market  Shingrix delivered growth +65% driven with HCPs and HCOs engagement to shape the category * Innovation = Oncology (Jemperli + Zejula) + New Respiratory (Nucala + Trelegy) + Adult Vaccines (Shingrix) 6 Source: GSK Standalone reported data Consistent competitive performance & profitability improvement with portfolio transformation 35.9 35.2 34.4 34.3 31.9 31.7 30.7 31.2 28.3 42YF 42YF 52YF 52YF 52YF 52YF 62YF 62YF 62YF 62YF 72YF Improving profitability Portfolio transformation EBITDA Margins% Category growth Market share % * Market share of Key promoted brands in its rep market; Key promoted brands - Augmentin, Calpol, Ceftum, T-bact, CCM, Cobadex CZS, Eltroxin, Tenovate,Neosporin, Supacef noitavonnI Est. Vx 27.9 28 27.6 27.4 27.8 27.4 27.6 27.8 26.5 27.1 26.3 Key promoted brands Source: Internal data till Mar 2026; IQVIA Jun’26 42YF 42YF 52YF 52YF 52YF 52YF 62YF 62YF 62YF 62YF 72YF Upcoming Launches Competitive performance gggssskkk...cccooommm End of Presentation